Imunon (NASDAQ: IMNN) — Perfil da empresa, notícias e dados financeiros
Imunon develops novel immunotherapies to treat various cancers, leveraging cutting-edge scientific research.

Imunon
Imunon (NASDAQ:IMNN) specializes in pioneering the development of novel immunotherapies aimed at treating a variety of cancers. With a focus on leveraging cutting-edge scientific research, Imunon strives to unlock new pathways in immune modulation to combat malignancies. The company's robust project pipeline is centered on advancing treatments that harness the body's own immune system to fight cancer more effectively. Imunon is firmly committed to its mission of bringing groundbreaking cancer therapies from the lab to the clinic, thereby aiming to improve patient outcomes and enhance quality of life for those battling cancer.
Resumo
Operações
Produtos e/ou serviços de Imunon
- LEAPS technology platform for vaccine development, focusing on autoimmune diseases and cancer.
- COVID-19 vaccine candidates, utilizing LEAPS for coronavirus variants.
- Therapeutic vaccines for Rheumatoid Arthritis, leveraging LEAPS platform.
- HIV vaccine development program, applying LEAPS technology for prevention.
- Inflammatory diseases treatment solutions, targeting conditions like Crohn's disease.
- Collaborations with academic and industry partners for advancing vaccine research and development.
equipe executiva do Imunon
- Michael H. TardugnoExecutive Chairman
- Stacy R. LindborgPresident, CEO & Director
- Douglas V. FallerChief Medical Officer
- Joshua BlacherInterim CFO, Principal Financial Officer & Principal Accounting Officer
- Kristin LongobardiSenior Vice President of Strategic Operations
- Stephen G. MachathaSenior Vice President of Technical Operations
Últimas notícias sobre a Imunon
Principais indicadores financeiros
Resultados divulgados pela Imunon, em USD.
- Cap. de mercado
- 21,3 mi
- Receita (TTM)
- 125 mil
- P/L
- —
- LPA (diluído, TTM)
- -3.8
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -14,7 mi | -14,5 mi | |
| 0 | -19,1 mi | -18,6 mi | |
| 125 mil | -21 mi | -19,5 mi | |
| 500 mil | -24,9 mi | -35,9 mi |